Demystifying Bio-Techne: Insights From 4 Analyst Reviews
Portfolio Pulse from Benzinga Insights
Bio-Techne (NASDAQ:TECH) has received mixed evaluations from 4 analysts over the past three months, with a combination of bullish and somewhat bullish ratings. The average 12-month price target has increased to $85.75, reflecting an 8.54% rise from the previous target. Analysts have adjusted their ratings and price targets based on recent market conditions and company performance.
May 22, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bio-Techne has received mixed analyst ratings over the past three months, with an average 12-month price target of $85.75, up 8.54% from the previous target. Analysts have adjusted their ratings and price targets based on recent market conditions and company performance.
The increase in the average price target and the mixed but generally positive analyst ratings suggest a favorable short-term outlook for Bio-Techne. The adjustments in ratings and price targets reflect analysts' reactions to recent market conditions and company performance, indicating potential for stock price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100